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Monoclonal Anti-CD18 Antibody Prevents Transcellular
Biosynthesis of Cysteinyl Leukotrienes In Vitro and In Vivo
and Protects Against Leukotriene-Dependent Increase in
Coronary Vascular Resistance and Myocardial Stiffness
Angelo Sala, PhD; Giuseppe Rossoni, MS; Ferruccio Berti, PhD; Carola Buccellati, PhD;
Albino Bonazzi, MS; Jacques Maclouf, PhD†; Giancarlo Folco, PhD
Background—Cysteinyl leukotrienes (cys-LT) can constrict small and large vessels and increase vascular permeability.
Formation of cys-LT arising from polymorphonuclear leukocytes (PMNL) and endothelial cell cooperation (transcel-
lular synthesis) led to the hypothesis that PMNL–endothelial cell adhesion may represent a key step toward the
formation of vasoactive cys-LT.
Methods and Results—We studied the effect of pretreatment with a monoclonal antibody directed against the CD18
subunit of PMNL b2-integrin on the synthesis of cys-LT in a PMNL-perfused isolated rabbit heart in vitro and in a model
of permanent ligature of the left descending coronary artery in the rabbit in vivo. Challenge of PMNL-perfused rabbit
hearts with formyl-met-leu-phe (0.3 mmol/L) caused synthesis of cys-LT and increase in coronary perfusion pressure
that were prevented by the anti-CD18 antibody. Similar results were obtained with the use of A-23187 (0.5 mmol/L) as
a challenge. Persistence of PMNL-associated myeloperoxidase activity in the perfusion buffer was observed in the
presence of the anti-CD18 antibody, indicating decreased PMNL infiltration. Coronary artery ligature in vivo increased
urinary excretion of leukotriene E4, supporting the activation of the 5-lipoxygenase pathway during experimental acute
myocardial infarction. Pretreatment with the anti-CD18 antibody (1 mg/kg) prevented the increase in leukotriene E4
excretion.
Conclusions—These data support the importance of adhesion in promoting cys-LT formation, originating from
PMNL–endothelial cell cooperation, and contributing to myocardial stiffness and increased coronary resistance.
(Circulation. 2000;101:1436-1440.)
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Adherence of polymorphonuclear leukocytes (PMNL) tovascular endothelial cells (EC) is one of the earliest
steps in inflammation in general and in the pathogenesis of
ischemia-reperfusion tissue injury.1 PMNL adherence to EC
involves several adhesion molecules that mediate cell-cell
interactions and orchestrate a complex series of events.2 The
activation of adherent leukocytes in response to various
stimuli characterizes the next step in an acute inflammatory
response involving diapedesis, release of proinflammatory
lipid mediators, alterations in vessel tone, and vascular
leakage. Several structurally diverse lipid molecules derived
from arachidonic acid are synthesized during inflammatory
reactions in vivo; among them, leukotrienes have attracted
considerable interest.3
Leukotriene C4, D4, and E4 (cys-LT) are potent vasoactive
mediators that constrict small and large vessels and modify
cardiac and coronary functions, the microcirculation, and
some of the manifestations of ischemia-reperfusion injury.4,5
Additionally, they have vasopermeant properties that might
be of relevance for the extravasation of leukocytes from the
vessel lumen to the tissue.6 Their generation exhibits remark-
able cellular specificity; however, cys-LT formation also may
occur through transfer of reactive intermediates between
adjacent cells, which represents a specialized mode of cell-
cell communication.7 PMNL-platelet interactions involving
the lipoxygenase pathway, which may be important in hemo-
stasis and inflammation, were first documented by Marcus et
al.8 More recently, cooperation of donor PMNL with acceptor
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EC in processing the reactive intermediate LTA4 into biolog-
ically active LTC4 has been demonstrated.9 This process has
been termed “transcellular biosynthesis” and suggests that the
cellular environment (ie, cell-cell interactions) represents an
important control mechanism in the production of eico-
sanoids, which may ultimately affect organ function.10 In-
deed, challenge of PMNL within the coronary vasculature
causes coronary vasoconstriction11 associated with PMNL
extravasation and widespread perivascular edema,12 both
dependent on endogenous cys-LT formation. PMNL-EC
adhesion is regulated by several cell-surface adhesion mole-
cules; among them PMNL b2-integrins are known to play a
significant role in firm adhesion of PMNL to EC.2
In the present study, we provide evidence that a monoclo-
nal antibody (mAb) directed against the CD18 subunit of
PMNL b2-integrins (a) inhibits cys-LT generation decreasing
PMNL-dependent tissue edema and coronary resistance in the
isolated heart of the rabbit in vitro and (b) inhibits the
increased urinary leukotriene excretion occurring after acute
myocardial infarction of the left ventricular wall in the rabbit
in vivo.
Results
Intravascular challenge of granulocyte macrophage-colony
stimulating factor (GM-CSF)–primed PMNL in the isolated
perfused heart with the chemotactic peptide formyl-met-leu-
phe (fMLP, 0.3 mmol/L) in the presence of a murine
nonbinding mAb (MOPC-21, 5 mg/mL) resulted in a signif-
icant increase of coronary resistance to perfusion (coronary
perfusion pressure, CPP), causing the arrest in systole in 3 of
4 isolated hearts within 30 to 45 minutes after challenge.
Basal left ventricular end-diastolic pressure (LVEDP) values
were very stable (560.2 mm Hg, n54) and increased mark-
edly after challenge (at 20 minutes, 55614.6 mm Hg, n54,
P,0.01 vs basal).
High-performance liquid chromatography (HPLC) analysis
of the total volume of the circulating perfusate (44 to 47 mL)
collected at the end of the experiment allowed positive
identification of cys-LT by on-line UV-spectrum analysis.
Pretreatment with the anti-CD18 antibody (6.5E, 5 mg/mL)
resulted in a significant inhibition of the increase in coronary
perfusion pressure (CPP), allowing survival of all isolated
hearts throughout the observation period of 60 minutes, and
was accompanied by a significant decrease in cys-LT forma-
tion (Figure 1). LVEDP values did not differ from basal
values (560.2 mm Hg, n54). The assay of cell-associated
myeloperoxidase (MPO) enzyme activity in the recirculating
buffer confirmed a rapid disappearance of MPO in the
presence of control mAb, whereas pretreatment with the
anti-CD18 mAb resulted in a significantly inhibited adhesion
of PMNL (Figure 2).
To test whether the observed effect of the anti-CD18
antibody could be reversed by a more sustained activation of
the 5-lipoxygenase (5-LO), PMNL-perfused, isolated hearts
were challenged with A-23187 (0.5 mmol/L). As previously
reported,11 challenge with A-23187 induced the PMNL-
dependent formation of cys-LT, together with a significant
increase in CPP, which resulted in arrest in systole in 3 of 4
isolated hearts within 20 to 30 minutes after challenge. As
observed with fMLP, pretreatment with the anti-CD18 mAb
significantly reduced the increase in CPP, and all isolated
hearts survived throughout the observation period of 30
minutes (Figure 3, left) and resulted in a marked suppression
of the formation of cys-LT (Figure 3, right), suggesting the
pivotal role of adhesion in their production.
The assay of circulating PMNL provided evidence of
efficacy of the pretreatment with the anti-CD18 antibody in
inhibiting PMNL adhesion. After A-23187 activation, a rapid
disappearance of PMNL from the recirculating buffer was
observed, suggesting intravascular adhesion. However, pre-
Figure 1. Effect of treatment with anti-CD18 mAb on PMNL-
dependent cys-LT formation and changes in coronary resistance
on challenge with fMLP in rabbit isolated heart. Isolated rabbit
hearts were reperfused with purified human PMNL (107 cells),
primed with GM-CSF (1 nmol/L, 30 minutes), and challenged
with fMLP (0.3 mmol/L) in presence of anti-CD18 mAb (6.5E, 5
mg/mL, M) or of isotype-matched, nonbinding control mAb
(MOPC-21, 5 mg/mL, E). CPP (left) was monitored continuously;
formation of leukotrienes (right) was evaluated by reverse-phase
HPLC of entire volume of recirculating perfusate. Values are
expressed as mean6SEM (n54). *P,0.05, **P,0.01 vs control.
Figure 2. Effect of treatment with anti-CD18 mAb on circulating
PMNL after challenge with fMLP. Isolated rabbit hearts were
reperfused with purified human PMNL (107 cells), primed with
GM-CSF (1 nmol/L, 30 minutes), and challenged with fMLP
(0.3 mmol/L) in presence of anti-CD18 mAb (6.5E, 5 mg/mL, M)
or of isotype-matched, nonbinding control mAb (MOPC-21, 5
mg/mL, E). PMNL-associated myeloperoxidase activity was
evaluated in aliquots of recirculating perfusate taken at 5, 10,
20, 30, 45, and 60 minutes after challenge. Values are
expressed as percent6SEM (n54) of MPO activity evaluated
immediately before challenge with fMLP. *P,0.05 vs control.
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treatment with the anti-CD18 mAb resulted in persistence of
PMNL-associated MPO activity in the recirculating buffer as
a result of inhibited adhesion (Figure 4).
Challenge with fMLP (0.3 mmol/L, 60 minutes) of GM-
CSF–primed PMNL preparations in suspension showed a
substantial release of LTA4 metabolites, which was not
affected by pretreatment with anti-CD18 mAb 6.5E
(25.563.4 vs 31.162.9 pmol/106 PMNL in control and
anti-CD18–treated cells, respectively; n53). Similarly, pro-
duction of LTA4 metabolites on challenge with A-23187
(0.5 mmol/L, 30 minutes) was not affected by pretreatment
with the anti-CD18 mAb (5 mg/mL21) (291.3613.7 vs
265.3610.3 pmol/106 PMNL in control and anti-CD18–
treated cells, respectively; n53).
In Vivo Studies
Excretion of LTE4 in urine was evaluated during the 3 hours
after permanent ligature of the left descending coronary
artery (coronary artery ligature, CAL) in the rabbit, resulting
in acute myocardial infarction of the left ventricular wall, and
was compared with the values obtained in sham-operated
animals. Urinary excretion of LTE4 was significantly higher
in the CAL group, treated with the nonbinding IgG1 mAb
MOPC-21 (1 mg/kg IV, 15 minutes before ligature), indicat-
ing endogenous production of cys-LT during the ischemia
associated with the coronary ligature. Treatment with the
anti-CD18 mAb 6.5E (1 mg/kg IV, 15 minutes before
ligature) fully prevented the increase in LTE4 excretion
(Figure 5).
Discussion
In the present study, we report that a mAb against the
functional epitopes of leukocyte CD18 complex of adhesive
glycoproteins prevents the generation of cys-LT taking place
through the interaction of PMNL with coronary EC. Cell
adherence may therefore represent an important mechanism
regulating leukotriene generation in situ and is in line with
our current understanding of cys-LT as paracrine hormones.
Neither PMNL nor EC can synthesize cys-LT from the
precursor AA; however, the former have been shown to
Figure 3. Effect of treatment with anti-CD18 mAb on PMNL-
dependent cys-LT formation and changes in coronary resistance
on challenge with A23187 in rabbit isolated heart. Isolated rabbit
hearts were reperfused with purified human PMNL (53106 cells)
and challenged with A23187 (0.5 mmol/L) in presence (M) or
absence (E) of pretreatment with anti-CD18 mAb (6.5E, 5
mg/mL). CPP (left) was monitored continuously; formation of leu-
kotrienes (right) was evaluated by reverse-phase HPLC of the
entire volume of recirculating perfusate. Values are expressed
as mean6SEM (n54). **P,0.01 vs control.
Figure 4. Effect of treatment with anti-CD18 mAb on circulating
PMNL after challenge with A23187. Isolated rabbit hearts were
reperfused with purified human PMNL (53106 cells) and chal-
lenged with A23187 (0.5 mmol/L) in presence (M) or absence (E)
of pretreatment with anti-CD18 mAb (6.5E, 5 mg/mL). PMNL-
associated MPO activity was evaluated in aliquots of recirculat-
ing perfusate taken at 5, 10, 20, and 30 minutes after challenge.
Values are expressed as percent6SEM (n54) of MPO activity
evaluated immediately before challenge with A23187. **P,0.01
vs control.
Figure 5. Urinary excretion of LTE4 after heart surgery in rab-
bits. Bladder was manually evacuated at beginning and 3 hours
after surgery to evaluate actual excretion of LTE4 after sham
operation or CAL. Coronary artery–ligated rabbits were either
treated with anti-CD18 mAb (6.5E, 1 mg/kg IV) or with isotype-
matched, nonbinding control mAb (MOPC-21, 1 mg/kg IV) 30
minutes before heart surgery and CAL. LTE4 was evaluated by
enzyme immunoassay on immunofiltration extraction. Values are
expressed as mean6SEM of total excretion of LTE4 (ng/h).
*P,0.05 vs sham operated.
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produce predominantly LTA4,13 whereas the latter possess a
remarkably effective metabolic capacity for cys-LT from the
epoxide precursor LTA4. It is therefore likely that during
adhesion, a privileged interface between the donor PMNL
and the acceptor EC is formed, creating the necessary
conditions to transfer the unstable intermediate LTA4. LTC4-
activated endothelium may then become adhesive for PMNL
through the surface expression of platelet-activating factor14
and P-selectin, providing a self-amplifying loop that may
result in increased transcellular synthesis of cys-LT.
The mechanism that explains the increase in coronary
vascular resistance and myocardial stiffness involves acti-
vated PMNL attaching to the vascular endothelium and
triggering transcellular biosynthesis of cys-LT; local forma-
tion of cys-LT results in edema formation and extravascular
compression of coronary microvessels, as previously shown
by scanning electron microscopy.12 Local production of
cys-LT also may contribute to active coronary vasoconstric-
tion; in fact, the increase in coronary perfusion pressure
evoked by PMNL activation is partially reversible after
intracoronary injection of sodium nitroprusside.11 The inhi-
bition of PMNL-EC adhesion by the anti-CD18 mAb, reduc-
ing cell-cell contact and making transcellular biosynthesis
events much less efficient, exerts protective effects against
cardiac inflammation and its functional outcomes.
We used the presence of cell-associated MPO activity as an
indirect tool to quantitatively evaluate the extent of PMNL
adhesion to its target cells and obtained evidence that anti-
CD18 mAb effectively blunted PMNL sequestration through
the coronary bed. A significant body of evidence supports the
notion that the inflammatory tissue damage that accompanies
ischemia or ischemia-reperfusion is mediated to a large extent
by PMNL.15 Accordingly, prevention of leukocyte-EC inter-
action, through the use of mAbs directed against adhesion
molecules, has proven successful in limiting ischemic dam-
age in experimental models.16,17 A study with isolated PMN-
L–glomerular EC coincubations showed that transcellular
synthesis of cys-LT was inhibited by pretreatment with an
anti-CD18 mAb.18 Our work extends these findings to a
functional organ system and provides a link between adhe-
sion of PMNL, synthesis of cys-LT, and functional
modifications.
The model of in vitro PMNL-dependent cardiac damage
used for this study is different from more complex in vivo
models of ischemia-reperfusion injury. Recently, a 54%
reduction in PMNL accumulation and a 57% decrease of
myocardial necrosis after ischemia-reperfusion was observed
in CD18-deficient mice and intracellular adhesion molecule-
1–deficient mice,19 supporting a critical role of these cell
adhesion molecules in myocardial cell injury of the reper-
fused myocardium. The more significant functional protec-
tion observed in our study (.80% inhibition of increase in
CPP and LVEDP) is not unexpected given the fact that our
model is uniquely PMNL dependent, whereas it is conceiv-
able that in vivo other cells and factors may contribute to the
development of the cardiac injury.
Measurement of LTE4 in urine has been largely adopted as
a noninvasive, time-integrated index of cysteinyl leukotriene
synthesis in vivo. Evaluation of urinary LTE4 excretion
showed a significant increase after permanent coronary liga-
ture in the rabbit, in agreement with the results of 2 indepen-
dent groups reporting increased urinary LTE4 excretion in
patients with coronary artery disease and in patients after
myocardial infarction.20,21 The observed inhibition after pre-
treatment with anti-CD18 antibody supports the hypothesis
that pathophysiologically relevant cys-LT formation within
an ischemic myocardium may represent the outcome of
transcellular biosynthetic events.
The increased urinary excretion of LTE4 associated with
the CAL observed in the present study is also clearly
complementary with our previous results with the same
model, in which we showed a significant decrease of the
mortality rate by pretreatment with a specific leukotriene
synthesis 5-lipoxygenase-activating protein (FLAP)
inhibitor.22
Although it may seem difficult to hypothesize the infiltra-
tion of neutrophils into the infarcted area in the time course
described, we must point out that under our working hypoth-
esis there is no need to have actual neutrophil infiltration, but
it would be sufficient for them to adhere to EC to achieve
local leukotriene formation associated with altered vascular
permeability and tone. In fact, it has recently been shown that
increased endothelial permeability occurs even in the absence
of neutrophil infiltration.23
The leukocyte count has been originally proposed as a
valuable routine index for the assessment of risk for myocar-
dial infarction.24 Since then, a number of epidemiological
studies have shown the existence of a significant relation
between blood white cell count and the occurrence of
coronary heart disease (eg, angina pectoris and myocardial
infarction).25 Furthermore, enhanced neutrophil expression of
CD11b/CD18 adhesion receptors has been recently reported
in patients with unstable angina.26 Our data, supporting the
functional relevance of CD18-mediated, PMNL-dependent
synthesis of cys-LT, provide a link between PMNL implica-
tion in the natural history of coronary heart disease and
increased urinary LTE4 levels in patients with cardiac ische-
mia, two observations apparently uncorrelated.
In conclusion, we propose that among the PMNL-
dependent factors contributing to the development of cardiac
damage associated with ischemia, the production of cys-LT
through transcellular biochemical mechanisms may have a
significant role and may represent a potential therapeutic
target.
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